Enclomiphene

Enclomiphene gets passed around fitness and “research chemical” circles as if it were a peptide or a sleek new-generation drug. It is neither. It is one of the two halves (isomers) that make up clomiphene — specifically the anti-estrogen half — and it is a small-molecule pill in a drug family called SERMs (selective estrogen receptor modulators, drugs that switch estrogen signaling on in some tissues and off in others). It is in the same chemical family as tamoxifen. The single most important thing to know about it is a legal one: despite years of development and real human trial data, it is not FDA-approved for anything. This page is for education and harm reduction. It gives no dosing, cycles, stacks, or post-cycle protocols, and no information on where to get it.

What it is

Enclomiphene (its official generic name is enclomifene) is the (E)-/trans-stereoisomer of clomiphene — one of two mirror-image versions of the same molecule. Clomiphene citrate (sold as Clomid) is not a single pure substance. It is a roughly 62:38 blend of enclomiphene — the anti-estrogen version — and zuclomifene, the slower-acting, estrogen-like Z-version. Enclomiphene is simply that “active anti-estrogen” portion pulled out on its own.

As a group, SERMs like this are oral, nonsteroidal drugs, and enclomiphene works by blocking estrogen’s signal at the hypothalamus and pituitary (two control centers in the brain that manage hormone levels). Here is the chain of events: normally, estrogen tells the brain to ease off on testosterone production — a kind of thermostat. By blocking that “ease off” signal, enclomiphene makes the brain release more GnRH (gonadotropin-releasing hormone, the brain’s start signal), which pushes the pituitary to release more LH and FSH (two hormones that tell the testes what to do). More LH and FSH means the testes make more of the body’s own testosterone, while FSH keeps sperm production going. In other words, the drug nudges a man’s own hormone system back to life. That is the deliberate contrast with taking testosterone from the outside (TRT, testosterone replacement therapy), which does the opposite — it shuts down LH, FSH, and sperm production. The drug clears the blood fairly quickly (a half-life of about 10 hours, peaking around 2-3 hours after a dose), but researchers have seen a lingering “after-effect” — raised testosterone and LH lasting at least about a week after stopping.

The claims

The medical idea behind it was narrow and specific: men with low testosterone plus low or oddly-normal LH — a condition called secondary (hypogonadotropic) hypogonadism — who want to keep their fertility and testicular size, especially younger men or men planning to have children. The selling point was that enclomiphene could raise a man’s own testosterone without the fertility-killing downside of TRT.

In the gym and bodybuilding world, SERMs like enclomiphene, clomiphene, and tamoxifen are used by people taking anabolic-androgenic steroids (AAS) to try to kick-start their own testosterone after a steroid cycle (“post-cycle”) by boosting LH and FSH, and to fight off estrogen-related side effects. As noted, this page does not provide doses, cycles, stacks, or post-cycle protocols.

What the evidence actually shows

The best data come from the Repros (Wiehle/Kim) trials in men with secondary hypogonadism, and they line up reasonably well on the hormone measurements:

• It reliably raises total testosterone into the normal (eugonadal) range, on par with testosterone gels you rub on the skin, and with less swing from person to person.
• It raises LH and FSH — where TRT shuts them down — and keeps or maintains sperm count and testicular size. That fertility-preserving contrast with TRT is the whole reason people find it interesting.

What it has not proven is the part that matters most for getting approved: lasting, FDA-grade real-world benefit (libido, energy, body composition) or solid fertility results like actual live births. The trials measured hormones and sperm counts — not pregnancies or long-term outcomes — and long-term safety data are thin. That is exactly the gap the FDA pointed to: the lab numbers moved, but whether that translated into a real benefit for these patients was never convincingly shown. That is why we grade this profile Preliminary human rather than “Strong” (grade 8–10): the hormone evidence is solid, but the drug never cleared the bar for proven real-world benefit, and it stays unapproved.

Legal and regulatory status

In the United States, enclomiphene is a prescription-only investigational drug that is not FDA-approved for any use. It is legal only when a doctor prescribes it off-label and a state-licensed pharmacy makes it up to order (this is called compounding, under rules known as 503A/503B). It is not sold over the counter, and it is not a finished, FDA-approved product. It is illegal to sell as a dietary supplement or “research chemical” — it is on the US Department of Defense Prohibited Dietary Supplement Ingredients List (per Operation Supplement Safety, the military’s supplement-safety program). It is not a controlled substance.

For legal context, here is how the compounds that often come up alongside it stack up:

• Clomiphene is an FDA-approved prescription drug — but only for triggering ovulation in women. It is not FDA-approved for men, where all use (like nearly all enclomiphene use) is off-label or compounded. Not a controlled substance.
• DNP (2,4-dinitrophenol) is NOT approved for people to consume. It was effectively pulled as a weight-loss drug around the time of the 1938 Federal Food, Drug, and Cosmetic Act after it caused deaths and cataracts, and it is now sold illegally online as a “fat burner.” It has a long, well-documented record of fatal poisonings.
• Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids and Schedule III controlled substances under the US Controlled Substances Act (the Anabolic Steroids Control Act of 1990, Pub. L. 101-647).

Safety

Enclomiphene / SERMs (risks shared across the drug class). In the short term, SERMs are generally well tolerated. The common side effects seen in trials include headache and mild mood or vision changes, and a modest drop in IGF-1 (a growth-related hormone) was noted. But the class-level concerns are real:

• Blood clots — thromboembolism (VTE / DVT / PE, clots in the veins or lungs) are a known concern for this drug class, well established with tamoxifen.
• Vision problems (blurring, flashes of light, and rarely a blocked retinal vein or damage to the optic nerve) are documented with clomiphene.
• The long-term safety of enclomiphene specifically is not established — there is no approval and limited long-term data. And because the whole mechanism works by dialing down estrogen signaling, pushing estrogen too low can hurt mood, libido, cholesterol (lipids), and bone over time.

Aromatase inhibitors (AIs), which come up in the same conversations, lower estrogen (estradiol) directly and can cause bone loss/osteoporosis, worse cholesterol numbers, joint pain, and libido or mood effects. In men, dropping estrogen too low is itself harmful.

DNP — the most dangerous compound here, and it kills people. It is a “mitochondrial uncoupler,” meaning it makes the body’s cells burn energy as runaway heat. The result is uncontrolled overheating (core body temperatures up to roughly 44 °C / 111 °F), a racing heart, severe acid buildup in the blood and breathing system, multi-organ failure, and death — sometimes within hours. There is NO specific antidote; doctors can only treat the symptoms (aggressive cooling and fluids). The gap between an “effective” amount and a deadly one is dangerously small, many deaths have been reported, and there is no safe human dose.

Insulin (misused by non-diabetics or for performance). Can cause severe, deadly low blood sugar (hypoglycemia) — confusion, seizures, coma, permanent brain damage, death. The danger comes on fast and is unforgiving.

Thyroid hormone (T3 / liothyronine) misused for fat loss risks heart rhythm problems, racing heart, atrial fibrillation, and reduced blood flow to the heart (ischemia), muscle breakdown, and shutting down the body’s own thyroid system (which can swing into an underactive thyroid after stopping).

Anabolic steroids (mesterolone, fluoxymesterone): liver damage (especially oral 17α-alkylated drugs like fluoxymesterone), worse cholesterol and heart risk, shutdown of the body’s hormone axis and infertility, breast tissue growth in men (gynecomastia), mood and aggression effects, and the development of male features (virilization).

None of this is medical advice.

Bottom line

Enclomiphene is a SERM — the anti-estrogen half of clomiphene — not a peptide and not a steroid. Human trials consistently show it raises testosterone, LH, and FSH and protects sperm production and testicular size, which is a genuine, meaningful difference from testosterone replacement. But it is not FDA-approved for any use: the FDA issued a Complete Response Letter in 2015 because the real-world benefit behind the hormone numbers was never convincingly shown, the EU recommended refusal in 2018, and the developer dropped it in 2021. Today it exists only as an off-label, compounded, investigational drug — not a controlled substance, but illegal to sell as a supplement or “research chemical.” In sport it is banned at all times. The hormone data are real; the proven real-world benefit and the approval are not.

Evidence grade: 8/10 · Good. Consistent human trial evidence that it raises testosterone while preserving fertility markers, but no proven durable clinical or fertility outcomes, no FDA approval, and limited long-term safety data.

Sources

• Wiehle RD, et al. 2013 — Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics (BJU Int 112(8):1188-1200; PMID 23875626; DOI 10.1111/bju.12363)
• Wiehle RD, et al. 2014 — Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II trial vs topical testosterone (Fertil Steril 102(3):720-727; PMID 25044085; DOI 10.1016/j.fertnstert.2014.06.004)
• Kim ED, McCullough A, Kaminetsky J. 2016 — Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone (BJU Int 117(4):677-685; PMID 26496621; DOI 10.1111/bju.13337)
• Hill S, Arutchelvam V, Quinton R. 2009 — Enclomiphene, an estrogen receptor antagonist for testosterone deficiency in men (IDrugs 12(2):109-119; PMID 19204885)
• Operation Supplement Safety (DoD) — Clomiphene and enclomiphene: Drugs, not dietary supplements
• ClinicalTrials.gov NCT00962637 — Safety and Efficacy of Androxal in Men With Secondary Hypogonadism (Sponsor: Repros Therapeutics)
• Enclomifene — Wikipedia (FDA non-approval, CHMP refusal, 2021 discontinuation)
• US Anabolic Steroids Control Act of 1990 (HR 4658, 101st Congress — AAS placed in Schedule III)
• WADA — The Prohibited List (S4 Hormone and Metabolic Modulators)
• Drugs.com — WADA S4: Hormone and Metabolic Modulators (S4.1 AIs; S4.2 SERMs/anti-estrogens incl. clomifene)
• USADA — Substance Profile: Clomiphene
• Viola MI, Meyer D, Kruger T. 2011 — Association between clomiphene citrate and visual disturbances, with emphasis on central retinal vein occlusion: a review (Gynecol Obstet Invest 71(2):73-76; PMID 21160153)
• Medsafe (NZ) — Tamoxifen and Venous Thromboembolism (supports SERM VTE concern)
• ATSDR Toxicological Profile for Dinitrophenols (Aug 2021)
• 2,4-Dinitrophenol — Wikipedia (1938 withdrawal; deaths; no antidote)
• Runaway uncoupling in 2,4-dinitrophenol poisoning: clinical and mitochondrial observations from two cases (Toxicol Rep 2025;16:102183)